Treatment for LSD Use
May 14, 2022 0 Comments
Treatment for LSD Use
Once a decision is made to obtain treatment, there are several steps to take.
- Speak to a healthcare provider to help direct you to reliable sources of help and monitor your progress.
- Talk therapy (behavioral counseling) and group counseling may be an option to help you understand your behaviors and why you continue to use LSD.
- Keep your appointments and follow your providers treatment plan. Consider including trusted family or friends in your treatment plan.
- Take care of yourself: exercise, eat healthfully, and control your stress level. Surround yourself with supportive people.
- Added medical therapy may be needed to treat symptoms due to drug use, such as anxiety, depression, or schizophrenia.
- Work to find new hobbies and interests that will take your mind off of drug use. Consider a volunteer opportunity.
- Each day make an effort to stay away from people who abuse drugs, even if they are former friends.
- National Institute on Drug Abuse (NIDA). Patients & Families. Treatment Resources.
- Partnership for Drug-Free Kids
- SAMHSA’s National Helpline – 1-800-662-HELP (4357)
- Bath Salts
- Devil’s Breath
- Fentanyl (Abuse/Overdose)
- Gray Death
- Hashish (Hash)
- MDMA (Ecstasy, Molly)
- Mescaline (Peyote)
- PCP (Phencyclidine)
- Psilocybin (Magic Mushrooms)
- Speed (methamphetamine)
- Synthetic Cannabinoids (Synthetic Marijuana, Spice, K2)
- TCP (Tenocyclidine)
- U-47700 (Pink)
- Blood Doping: Lance Armstrong and the USPS Pro Cycling Team
- Can a Drug Test Lead to a False Positive?
- Drug and Substance Abuse
- Understanding Opioid (Narcotic) Pain Medications
- Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. Accessed Jan. 28, 2020 at https://www.samhsa.gov/data/release/2018-national-survey-drug-use-and-health-nsduh-releases
- Monitoring the Future 2019 Survey Results: Overall Findings. National Institute on Drug Abuse (NIDA).
- Substance Abuse and Mental Health Services Administration, National Survey on Drug Use and Health: Trends in Prevalence of Various Drugs for Ages 12 or Older, Ages 12 to 17, Ages 18 to 25, and Ages 26 or Older; 2015 – 2016 (in percent). Accessed Jan. 28, 2020 at https://www.drugabuse.gov/national-survey-drug-use-health
- LSD. U.S. Drug Enforcement Agency (DEA). Accessed August 30, 2018 at https://www.dea.gov/factsheets/lsd
- National Institute on Drug Abuse (NIDA). Research report series: hallucinogens and dissociative drugs. Accessed Jan. 28, 2020 at https://www.drugabuse.gov/sites/default/files/hallucinogensrrs.pdf. Updated January 2014.
- How Widespread Is the Abuse of Hallucinogens and Dissociative Drugs? National Institute on Drug Abuse (NIDA). Accessed Jan. 28, 2020 at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/why-do-people-take-hallucinogens
- Hallucinogens and Dissociative Drugs. From the Director. National Institute on Drug Abuse (NIDA). Accessed Jan. 28, 2020 at https://www.drugabuse.gov/publications/research-reports/hallucinogens-dissociative-drugs/director
- Substance use – LSD. MedLine Plus. U.S. National Library of Medicine. Accessed August 30, 2018 at https://medlineplus.gov/ency/patientinstructions/000795.htm
- LSD Overdose. Drugabuse.com. Accessed August 30, 2018 at https://drugabuse.com/lsd/overdose/
- LSD. NZ Drug Foundation. Accessed Jan. 28, 2020 at https://www.drugfoundation.org.nz/info/drug-index/lsd/
- Psychedelic Amazonian Drug, Ayahuasca, Might Ease Symptoms of Depression, Alcoholism. Drugs.com. Nov. 14, 2017. Accessed August 31, 2018.
- Hallucinogens. National Institute on Drug Abuse (NIDA). Accessed Jan. 28, 2020 at https://www.drugabuse.gov/publications/drugfacts/hallucinogens
- Fuentes Juan José, Fonseca Francina, Elices Matilde, Farré Magí, Torrens Marta. Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials . Frontiers in Psychiatry 2020(10):943 https://www.frontiersin.org/article/10.3389/fpsyt.2019.00943